Dr. Vyshali S. Rao
Huntington Memorial Hospital is the first facility in the San Gabriel Valley
to implant a new miniaturized, wireless monitoring sensor to manage heart
failure (HF). The CardioMEMS HF System is the first and only FDA-approved
heart failure monitoring device that has been proven to significantly
reduce hospital admissions when used by physicians to manage heart failure.
The CardioMEMS HF System features a sensor that is implanted in the pulmonary
artery (PA) during a non-surgical procedure to directly measure PA pressure.
Increased PA pressures appear before weight and blood pressure changes,
which are often used as indirect measures of worsening heart failure.
The new system allows patients to transmit daily sensor readings from
their homes to their health care providers allowing for personalized and
proactive management to reduce the likelihood of hospitalization.
“CardioMEMS is an exciting and valuable tool and we are proud to
bring this specialized care to our patients and the community,” said
Dr. Vyshali S. Rao, interventional cardiologist, who performs the procedure. “This
innovative technology helps our physicians to treat and offers improved
outcomes for heart failure patients.”
Heart failure occurs when the heart is unable to pump enough blood to meet
the body’s demands. According to the Centers for Disease Control
and Prevention, more than 5.1 million Americans have heart failure, with
670,000 new cases diagnosed each year. Patients with heart failure are
frequently hospitalized, have a reduced quality of life and face a higher
risk of death.
The CardioMEMS sensor is designed to last the lifetime of the patient and
doesn’t require batteries. Once implanted, the wireless sensor sends
pressure readings to an external patient electronic system. There is no
pain or sensation for the patient during the readings. The CardioMEMS
HF System allows the patients to transmit critical information about their
heart failure status to a clinician on a regular basis, without the need
for additional clinic or hospital visits. This provides clinicians with
the ability to detect worsening heart failure sooner and adjust treatment
to reduce the likelihood that the patient will need to be hospitalized.
Data from a clinical trial showed that the CardioMEMS technology reduces
heart failure hospital admissions by up to 37 percent. The CHAMPION trial
studied the effectiveness of the CardioMEMS HF System in New York Heart
Association (NYHA) Functional Classification System class III heart failure
patients who had been hospitalized for heart failure in the previous 12
months. Results of the trial demonstrated a statistically significant
28 percent reduction in the rate of heart failure hospitalizations at
six months, and 37 percent reduction in heart failure hospitalizations
during an average follow-up duration of 15 months.
Roughly 1.4 million patients in the U.S. have NYHA Class III heart failure,
and historically these patients account for nearly half of all heart failure
hospitalizations. According to the American Heart Association, the estimated
direct and indirect cost of heart failure in the U.S. for 2012 was $31
billion and that number is expected to more than double by 2030.
The CardioMEMS HF System, from global medical device manufacturer St. Jude
Medical, is approved by the U.S. Food and Drug Administration (FDA) for
commercial use in the U.S. For more information, please click